Last updated on April 2018

Immune Response to Shingles Vaccination

Brief description of study

The purpose of this study is to learn more about the immune response to varicella zoster virus (VZV).

Detailed Study Description

Participants 70 years of age or older will receive the FDA-approved shingles vaccine (Zostavax). Blood samples and optional skin biopsies will be obtained before and after vaccination to study the immune responses to shingles vaccination.

Clinical Study Identifier: NCT02624375

Contact Investigators or Research Sites near you

Start Over

Christine Johnston, MD, MPH

University of Washington Virology Research Clinic
Seattle, WA United States
  Connect »